Näytä suppeat kuvailutiedot

dc.contributor.authorBlomqvist, Carl
dc.contributor.authorVehmanen, Leena
dc.contributor.authorKellokumpu-Lehtinen, Pirkko-Liisa
dc.contributor.authorHuovinen, Riikka
dc.contributor.authorRuohola, Johanna
dc.contributor.authorPenttinen, Heidi
dc.contributor.authorSievänen, Harri
dc.contributor.authorNikander, Riku
dc.contributor.authorUtriainen, Meri
dc.contributor.authorSaarto, Tiina
dc.date.accessioned2024-04-12T11:55:38Z
dc.date.available2024-04-12T11:55:38Z
dc.date.issued2024
dc.identifier.citationBlomqvist, C., Vehmanen, L., Kellokumpu-Lehtinen, P.-L., Huovinen, R., Ruohola, J., Penttinen, H., Sievänen, H., Nikander, R., Utriainen, M., & Saarto, T. (2024). Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients : 10-year follow-up results of the BREX study. <i>Breast Cancer Research and Treatment</i>, <i>Early online</i>. <a href="https://doi.org/10.1007/s10549-024-07252-7" target="_blank">https://doi.org/10.1007/s10549-024-07252-7</a>
dc.identifier.otherCONVID_207877257
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/94289
dc.description.abstractPurpose We aimed to provide long-term bone mineral density (BMD) data on early breast cancer patients of the BREX (Breast Cancer and Exercise) study. The effects of exercise and adjuvant endocrine treatment 10 years after randomization were analyzed, with special emphasis on aromatase inhibitor (AI) therapy discontinuation at 5 years. Methods The BREX study randomized 573 pre- and postmenopausal breast cancer patients into a 1-year supervised exercise program or a control group. 372 patients were included into the current follow-up analysis. BMD (g/cm2) was measured by dual-energy X-ray absorptiometry at lumbar spine (LS), left femoral neck (FN), and the total hip. Separate groups were displayed according to baseline menopausal status, and whether the patient had discontinued AI therapy at 5 years or not. Results The BMD change from 5 to 10 years did not significantly differ between the two randomized arms. AI discontinuation at 5 years had statistically significant BMD effects. The FN BMD continued to decrease in patients who discontinued AI therapy during the first 5-year off-treatment, but the decrease was three-fold less than in patients without AI withdrawal (− 1.4% v. − 3.8%). The LS BMD increased (+ 2.6%) in patients with AI withdrawal during the first 5 years following treatment discontinuation, while a BMD decrease (-1.3%) was seen in patients without AI withdrawal. Conclusion This study is to our knowledge the first to quantify the long-term impact of AI withdrawal on BMD. Bone loss associated with AI therapy seems partially reversible after stopping treatment. Trial registration: http://www.clinicaltrials.gov/ (Identifier Number NCT00639210).en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesBreast Cancer Research and Treatment
dc.rightsCC BY 4.0
dc.subject.otheraromatase inhibitor withdrawal
dc.subject.otherbone loss
dc.subject.otherbreast cancer
dc.titleLong-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients : 10-year follow-up results of the BREX study
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202404122862
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn0167-6806
dc.relation.volumeEarly online
dc.type.versionpublishedVersion
dc.rights.copyright© 2024 the Authors
dc.rights.accesslevelopenAccessfi
dc.subject.ysoluuntiheys
dc.subject.ysoosteoporoosi
dc.subject.ysotekoäly
dc.subject.ysorintasyöpä
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p22879
jyx.subject.urihttp://www.yso.fi/onto/yso/p10781
jyx.subject.urihttp://www.yso.fi/onto/yso/p2616
jyx.subject.urihttp://www.yso.fi/onto/yso/p20019
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1007/s10549-024-07252-7
jyx.fundinginformationOpen Access funding provided by University of Helsinki (including Helsinki University Central Hospital). This work was supported by Cancer Society of Finland, Finnish Cancer Foundation, Academy of Finland, Comprehensive Cancer Center of Helsinki University Central Hospital, Social Insurance Institution of Finland, Finnish Ministry of Education, Finska Läkaresällskapet, Special Government Grant for Health Science Research (Finland), Helander Foundation, Paulo Foundation, Finnish Cultural Foundation, Medical Fund of the Pirkanmaa Hospital District, and Finnish Breast Cancer group. Astra Zeneca (FI) sponsored step benches for the study.
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY 4.0